Cargando…

Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc

INTRODUCTION: Nucleoside reverse transcriptase inhibitor (NRTI) is associated with endothelial dysfunction and proinflammatory effects. Maraviroc (MVC) is an antagonist of CCR5 receptor. CCR5 is the receptor of RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted), a mediator of chr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernal, Enrique, Miguel Gomez Verdú, Jose, Vera, Francisco, Martinez, Onofre, Bravo, Joaquin, Galera, Carlos, Muñoz, Angeles, Garcia, Eva, Serrano, Jose, Perez, Ana, Vera, Carmen, Marín, Irene, Cano, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P194
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225394/ https://www.ncbi.nlm.nih.gov/pubmed/25397472 http://dx.doi.org/10.7448/IAS.17.4.19726

Ejemplares similares

The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment
por: Bernal, Enrique, et al.
Publicado: (2014)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Hemostatic bitherapy for spurting bleeding
por: Katsanos, Konstantinos H., et al.
Publicado: (2012)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

Impact of NRTI backbone on renal, bone and cardiovascular markers in HIV-infected individuals receiving a boosted protease inhibitor
por: Barber, Tristan, et al.
Publicado: (2014)

The state of PI monotherapy and NRTI-sparing therapy
por: Arribas, JR
Publicado: (2010)

An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen
por: Aragão, F, et al.
Publicado: (2010)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
por: Henrivaux, Philippe, et al.
Publicado: (2010)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens
por: Gonzalez-Serna, A., et al.
Publicado: (2017)

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study
por: Carrero-Gras, Ana, et al.
Publicado: (2014)

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
por: Torti, Carlo, et al.
Publicado: (2011)

The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI
por: Liu, Shengnan, et al.
Publicado: (2023)

REVISITING HYPERSENSITIVITY REACTIONS TO THE MRNA COVID-19 VACCINE: TOLERANCE AFTER PREVIOUS HISTORY OF ANAPHYLAXIS
por: AlOtaibi, I., et al.
Publicado: (2022)

Evaluation of the degree of liver fibrosis and genetical characteristics in HIV patients with spontaneous clearance of HCV in Cartagena, Spain
por: Jesús Vera Méndez, Francisco, et al.
Publicado: (2014)

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study
por: Podzamczer, Daniel, et al.
Publicado: (2014)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

HTA and HIV: The Case of Dual NRTI Backbones in the Italian Setting
por: Garagiola, Elisabetta, et al.
Publicado: (2020)

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC
por: Ramón Santos, José, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

Incremental cost per newly diagnosed HIV infection (NDHI): routine (RTS), targeted (TTS), and current clinical practice testing strategies (CPTS)
por: Gomez-Ayerbe, Cristina, et al.
Publicado: (2014)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future
por: Dieterich, Douglas T
Publicado: (2006)

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study
por: Pérez Valero, Ignacio, et al.
Publicado: (2014)

Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study
por: Cahn, Pedro, et al.
Publicado: (2014)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study
por: Minguez, Carlos, et al.
Publicado: (2014)

Facial emotional processing deficits in long-term HIV-suppressed patients
por: Gonzalez-Baeza, Alicia, et al.
Publicado: (2014)

Overall and cause-specific mortality in HIV-positive subjects compared to the general population
por: Alejos, Belen, et al.
Publicado: (2014)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults
por: Gatell, Josép M, et al.
Publicado: (2014)

Use of deep sequencing data for routine analysis of HIV resistance in newly diagnosed patients
por: Fernández-Caballero, Jose-Angel, et al.
Publicado: (2014)

High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients
por: Bossard, Claire, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4lq23ucmh98pkf3cvfk2ist36m